• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Q1 stock sales generate $14 million for Boston Scientific co-founders

Q1 stock sales generate $14 million for Boston Scientific co-founders

April 7, 2010 By Dave Price

BSX logo

John Abele and Peter Nicholas were slated to sell 100,000 shares each of Boston Scientific Corp. (NYSE:BSX) stock this week, exactly a year to the day that the retired executives initiated the transactions through separate forward-sale contracts.

The transfers have become familiar activity for the Boston Scientific co-founders over the past 18 months. They both have two more 100,000-share contracts ready to mature this month, and between them formally turned over possession of 2.25 million shares during the first three months of 2010. Overall, the deals generated slightly more than $8.1 million in gross proceeds for Abele and added about $7.1 million to Nicholas’ bank accounts.

The April 6 settlements were not the only forays into the market by the pair in recent months. The retired executives sold a total of 800,000 Boston Scientific shares during the quarter — 600,000 shares by Abele and 200,000 shares by Nicholas — through a process known as 10b5-1 sales, which allow company insiders to sell stock over extended periods through a series of pre-arranged transactions. They also executed a new set of forward-sale contracts, with Abele pocketing nearly $5 million by pledging to sell nearly 1 million shares to an unidentified bank in March 2012. Nicholas similarly enjoyed a $4.6 million payday after making just under 900,000 shares available for future sale, also in 2012.

Abele, 73, has been a director at Boston Scientific since its 1979 launch and retired from the Natick, Mass.-based device manufacturer in 1995. Nicholas, 68, also remains a director after stepping down in 1999 following a 20-year stint as CEO.

As recently as three years ago, Nicholas controlled nearly 94 million shares, or about 6.4 percent of all Boston Scientific stock, mostly through a family limited partnership. At its peak, when the stock was topping out close to $45 a share, his net worth — at least on paper — had climbed past $4.5 billion. Abele, meanwhile, has owned as many as 58.4 million shares of the company’s stock and was worth roughly $2.5 billion at the stock’s high-water mark in May 2004.

Through April 1, Nicholas had pared his stake to roughly 21.4 million shares and Abele owned about 8 million shares, according to securities filings.

To reach those levels, Abele moved 600,000 shares through 10b5-1 sales during the first quarter, resulting in $4.2 million in proceeds. Coupled with proceeds from the 980,000 shares he intends to sell through forward-sale contracts maturing in 2012, his total take for the quarter was $9.2 million. Abele also made good on $8.1 million in forward-sale contracts he initiated during the first three months of 2009, delivering 1.13 million shares to the unidentified bank that coordinated the transactions.

Nicholas pocketed about $6 million during the quarter. He sold 200,000 shares through the 10b5-1 process at an average price of $7.03 per share, producing $1.4 million in proceeds, and set up forward-sale contracts paying $4.6 million in exchange for nearly 900,000 shares slated for delivery in March 2012. He previously received about $7.1 million for the 1 million-plus shares delivered between Jan. 7 and March 30 to complete his forward-sale contracts.

Filed Under: Business/Financial News, News Well Tagged With: Boston Scientific

In case you missed it

  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit
  • Stereotaxis stock down amid cloudy outlook
  • BD, Labcorp collaborate on flow cytometry-based diagnostics
  • NeuroOne submits special FDA 510(k) application for Evo sEEG electrode
  • Si-Bone grows sales 15% in Q2
  • FDA approves second IDE study for CereVasc eShunt
  • Nuwellis posts Q2 sales beat
  • Avanos Medical updates full-year revenue guidance on mixed-bag Q2 results
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • Conformis rises on in-line Q2 results
  • ICU Medical stock sinks on Q2 misses, slashed 2022 guidance
  • Vicarious Surgical completes Beta 2 system design
  • Asensus Surgical says procedures up by more than a third in Q2
  • MRI pioneer Dr. Raymond Damadian dies at 86
  • BD makes tender offers for up to $500M of its debt
  • ViewRay moves HQ to Denver
  • Abbott is looking to address biases for cardiovascular patients

RSS From Medical Design & Outsourcing

  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]
  • New method of cardiac ablation used in first in-human trial for ventricular tachycardia
    A new cardiac ablation technique for patients with ventricular tachycardia (VT) has been used in its first in-human multicenter trial involving Mayo Clinic. The new process — needle ablation using in-catheter, heated, saline-enhanced, radio frequency (SERF) energy — creates lesion scars inside the heart muscle where life-threatening arrhythmias cause VT, Mayo Clinic said. Injecting heated saline… […]
  • AdvaMed pushes CMS for proposed TCET pathway rule this year
    The Advanced Medical Technology Association (AdvaMed) is asking the Centers for Medicare & Medicaid Services (CMS) to move fast on a new way to guarantee reimbursement for new medtech innovations. CMS repealed the Medicare Coverage of Innovative Technology (MCIT) program last year but promised to explore other options to improve the coverage process for access… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy